الفهرس 
Serologic assessment of antibody responses to SARS-CoV-2 in convalescent patients with different severities of coronavirus disease 2019
ContentsOnly 14 pages are availabe for public view
 |  | from | 213 |  |  |
| | | from | 213 | | |
Abstract
The COVID-19 pandemic has had devastating effects onthe global healthcare system, prompting calls for diagnostic tools to trackand study the disease’s spread, pathophysiology, and epidemiology. Forthe developmentof avaccine, a better understanding of the antibodyresponse to SARS-CoV-2inaninfectedpopulationiscritical.
Aim: this study aims at assessing the anti‐SARS‐CoV‐2 specific antibody(totalimmunoglobulins,IgGandneutralizingantibodies)responseinconvalescent-COVID‐19 patients and the relation between specific antiSARSCOV2 antibodyresponseand severityofthedisease.
Methods:This is a retrospective descriptive study that included 198-COVID-19-recoveredpatientsduringtheperiodfromMay2020toDecember2020.ConvalescentpatientshadaprevioushistoryofconfirmedSARS-COV2infection whowererecruited28daysfrombeing RT-PCR negative for SARS-COV2. In our study, the convalescentindividualswereclassifiedintothreecategoriesaccordingtodiseaseseverity;mild,moderateandsevere(41.4%),(18.2%)and(40.4%),respectively.Aftergiving informed consent,all enrolled cases meetingthe criteria for negative nucleic acid tests on respiratory tract samples fivemillilitersofvenousbloodsampleswerewithdrawn,centrifuged,separated serum evacuated into one tube for specific anti SARS COV2antibody levels (Total Ig, IgG and neutralizing antibodies) using VITROSchemiluminescentimmunoassaytestandforneutralizingantibodies.
Results:Thedetectionrateofanti-SARS-CoV-2IgGandtotalIgantibodies was 55.6% and 85.9%, respectively and Out of 37 patients,91.9%(34/37)haddevelopedSARS-CoV-2–neutralizingAbs.Anti-SARS-CoV-2 total Ig titers correlate with disease severity (p = 0.02). Foranti-SARS-CoV-2IgGandnAbstiterstherewasnosuchcorrelation(p=
0.8andp=0.63, respectively).
Conclusion:There is a correlation between disease severity and level ofantiSARS-CoV-2totalIgtitersbutnotwithIgGornAbstitersinconvalescent patients.